Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reiterated by research analysts at Maxim Group in a research report issued to clients and investors on Wednesday. They presently have a $4.00 price target on the biotechnology company’s stock. Maxim Group’s price objective points to a potential upside of 354.55% from the company’s current price.

The analysts wrote, “Capricor reported 3Q18 with a net loss of ($4.1M) and ended the period with $10.4M in cash on the balance sheet, runway into 2Q18. We do expect that the company will need to raise capital in early 2019, prior to reaching data for the HOPE-2 study, which is expected in 2020.””

CAPR has been the subject of several other reports. Zacks Investment Research cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 21st. TheStreet cut shares of Capricor Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, October 15th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Capricor Therapeutics presently has a consensus rating of “Buy” and an average target price of $4.83.

CAPR opened at $0.88 on Wednesday. Capricor Therapeutics has a 1 year low of $0.66 and a 1 year high of $2.48.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Capricor Therapeutics had a net margin of 24.75% and a negative return on equity of 146.11%. The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.90 million. Analysts forecast that Capricor Therapeutics will post -0.53 EPS for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Recommended Story: Balanced Fund

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.